Pseudoephedrine Prophylaxis for Prevention of Middle Ear Barotrauma in Hyperbaric Oxygen Therapy

Phase 4

Completed

Conditions: Barotrauma;Ear

Interventions: Procedure: Hyperbaric Oxygen Therapy
Drug: Pseudoephedrine 60 MG
Drug: Placebo oral tablet

Registration Number: NCT04332211

Lead Sponsor: University of Maryland, Baltimore

Brief Summary: Hyperbaric oxygen therapy (HBOT) utilizes 100% oxygen delivery at a pressure greater than 1 atm for the treatment of various emergent medical conditions including carbon monoxide poisoning. The most commonly associated complication of HBOT is middle ear barotrauma (MEB) which occurs when the eustachian tube does not allow air to enter the middle ear space to equalize the pressure between the ambient environment and the inner ear. Patients experiencing MEB usually feel pressure or pain in their ear(s). The spectrum of symptoms ranges from sensation of ear fullness and muffled hearing to severe pain, vertigo and tympanic membrane rupture. The incidence of MEB, depending on the definition used is between 2-45%. The severe discomfort associated with MEB sometimes causes HBOT to be postponed or abandoned. Last year 27/991 treatments at our Center for Hyperbaric and Dive Medicine were aborted due to MEB. Currently there is no objective criteria for predicting which patients will experience these complications, nor is there consensus on effective prevention measures. At our facility, oxymetazoline, a topical nasal decongestant, is the standard rescue medication administered for patients that have symptoms of MEB during HBOT. This is despite two negative studies showing that this medication does not work any better than placebo. Other studies involving scuba divers and airplane travelers showed that oral pseudoephedrine is effective in decreasing MEB. However, the use of pseudoephedrine for patients undergoing HBOT has not been studied. The investigators plan to perform a randomized double blind placebo control trial to determine if pseudoephedrine is effective in decreasing the rate of MEB during HBOT.

Detailed Description: Aim 1: To investigate the efficacy of pre-treatment with oral pseudoephedrine 60mg for decreasing MEB during HBOT.

Hypothesis: Patients randomized to pseudoephedrine will have a lesser need for oxymetazoline rescue therapy while being compressed. They will also report less ear pain once at pressure compared to patients receiving placebo.

Aim 2: To measure the incidence of MEB during HBOT. The investigators will also identify factors (age, gender, medical history) that could predispose an individual to developing MEB during HBOT.

Hypothesis: The incidence of MEB defined as requiring stopping compression of the chamber and oxymetazoline rescue will be greater than 30%. Female sex, age above 60, and prior history of ear conditions will be associated with development of MEB.

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 105

Inclusion Criteria

New patient requiring HBOT (either inpatient or outpatient)
Age greater than or equal to 18 years and less than 80 years
Fluent in English
Full decision capacity
Able and medically cleared to swallow a pill

Exclusion Criteria

Contraindication to pseudoephedrine (MAOI use, pregnancy, glaucoma, heart disease, allergy to drug class)
SBP >160
DBP > 90
HR >100
Decongestant/antihistamine/pseudoephedrine/nasal steroid/oxymetazoline use within 12 hours.
Prisoner
Intubated
Unable take PO meds

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Pseudoephedrine Group	Hyperbaric Oxygen Therapy	Patients randomized to pseudoephedrine prior to hyperbaric therapy
Pseudoephedrine Group	Pseudoephedrine 60 MG	Patients randomized to pseudoephedrine prior to hyperbaric therapy
Placebo Group	Hyperbaric Oxygen Therapy	Patients randomized to placebo prior to hyperbaric therapy
Placebo Group	Placebo oral tablet	Patients randomized to placebo prior to hyperbaric therapy

Primary Outcome Measures

Name	Time	Method
Requirement of Oxymetalozine Rescue for Ear Pain During Hyperbaric Therapy Compression	12 minutes	middle ear barotrauma will be sensed as pain and inability to "clear" the ear to pressure during chamber pressurization. If the patient requires rescue oxymetazoline nasal spray therapy (usual care) they will be counted as having developed middle ear barotrauma.

Secondary Outcome Measures

Name	Time	Method
Middle Ear Barotrauma Documentation Based on Otoscopy	1 minute	visual inspection of the tympanic membrane after completion of hyperbaric oxygen therapy by the attending physician and classification based on the Teed score. We are only measuring no injury versus any injury.
Patient Description of Ear Pain	1 minute	Patients will be asked to provide a numerical scale level of pain before and after hyperbaric therapy. The scale is from 0 to 10. We only are interested in no pain versus presence of any pain.